This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Cryoport, Inc. ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, announced that the Company's best-in-class logistics solution is supporting Kite Pharma's ("Kite") clinical program for their lead product candidate, KTE-C19, a CAR-T cell therapy for non-Hodgkin's lymphoma ("NHL").
Kite is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T cell therapy (eACT(TM)) designed to restore the immune system's ability to recognize and eradicate tumors.
David Chang, M.D., Ph.D., Kite's Executive Vice President of Research and Development and Chief Medical Officer, commented, "Cryoport has provided valuable cryogenic logistics solutions for our lead clinical program. We are grateful for their professionalism and their support in a role that is contributing greatly to our progress."
Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "We are honored to provide services and solutions to Kite in their efforts to advance a novel immunotherapy treatment that addresses the significant, unmet needs of patients with NHL. We are delighted that Cryoport's validated cryogenic logistics solutions will support Kite in moving closer to eradicating this deadly disease."
>> For more information, click here
